Palatin Technologies Inc. (PTN)

[apollo1452]

"Phase2b baseline was the 4-week single-blind placebo period.

The Primary Efficacy Endpoint was Change From Baseline to End of Study in the Number of Satisfying Sexual Events.

A Secondary Outcome Measure was the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?" The score range is 1 (very much worse) to 7 (very much better)."

This is from clinicaltrials.gov, sorry that my attempt to post the link was unsuccessful. My interpretation is that All Phase2b Patients took Brem after their placebo baseline was established. That means the "85% comment" from CEO Spana is very significant IMO.